The Dental and Pharmaceutical Benefits Agency (TLV) was commissioned in the 2019 appropriation directions to continue the follow-up of cancer pharmaceuticals and other pharmaceuticals in clinical practice. The assignment was reported on 1 October 2020. TLV’s work is a continuation of previous assignments relating to follow-up, reported in November 2018. There are follow-up work in this field planned to be reported by 1 May 2021.
The ability to follow-up on the utilisation of pharmaceuticals and treatment effects is a prerequisite for ensuring TLV is able to contribute to the rapid and equal access to new pharmaceuticals and ensuring as many people as possible have access to treatment. Follow-up is also a prerequisite for being able to ensure that the cost of using a pharmaceutical is reasonable in relation to the benefit, not only in subsidy decisions but also throughout the entirety of a pharmaceutical’s life cycle. Health care providers and patients expect access to innovative new pharmaceuticals. Since subsidy applications for these pharmaceuticals often include uncertainties about treatment effects and how the pharmaceutical will be utilised, TLV must be able to carry out high quality follow-up.
This report contains the results from seven pilot studies along with the lessons learned from the work on the pilot studies as well as from TLV’s other work to expand the use of data from clinical practice. We also describe where continued work is needed. An in-depth description of the pilot studies is presented in the appendices to this report (in Swedish only).